Related references
Note: Only part of the references are listed.EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review
P. Quirke et al.
VIRCHOWS ARCHIV (2014)
The relation between lymph node status and survival in Stage I-III colon cancer: results from a prospective nationwide cohort study
J. Lykke et al.
COLORECTAL DISEASE (2013)
Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5′fluoruracil-based adjuvant chemotherapy
Maria Dolores Giraldez et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database
Qian Shi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
Frank A. Sinicrope et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Localized Colon Cancer, Version 3.2013 Featured Updates to the NCCN Guidelines
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer
Eric J. Th Belt et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
The prognostic importance of miR-21 in stage II colon cancer: a population-based study
S. Kjaer-Frifeldt et al.
BRITISH JOURNAL OF CANCER (2012)
Prognostic Impact of Lymph Node Harvest and Lymph Node Ratio in Patients With Colon Cancer
Ole H. Sjo et al.
DISEASES OF THE COLON & RECTUM (2012)
Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients
Claudio Coco et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Interventions to Improve Care Related to Colorectal Cancer Among Racial and Ethnic Minorities: A Systematic Review
Keith Naylor et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2012)
Factors predicting oncologic outcomes in patients with fewer than 12 lymph nodes retrieved after curative resection for colon cancer
Jung Wook Huh et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Prognostic Impact of Fascin-1 Expression is More Significant in Advanced Colorectal Cancer
Seung Yeop Oh et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
Arnaud D. Roth et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Prognostic Factors Assessed for 15,096 Patients with Colon Cancer in Stages I and II
Pawel Mroczkowski et al.
WORLD JOURNAL OF SURGERY (2012)
Folate Intake, MTHFR Polymorphisms, and the Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis
Deborah A. Kennedy et al.
JOURNAL OF CANCER EPIDEMIOLOGY (2012)
Prediction of Prognosis Is Not Improved by the Seventh and Latest Edition of the TNM Classification for Colorectal Cancer in a Single-Center Collective
Ulrich Nitsche et al.
ANNALS OF SURGERY (2011)
Prognostic Impact of Inferior Mesenteric Artery Lymph Node Metastasis in Colorectal Cancer
Jeonghyun Kang et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis
Daniel J. Sargent et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival
Helgi Birgisson et al.
BMC CANCER (2011)
Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer
Motofumi Tanaka et al.
CLINICAL CANCER RESEARCH (2011)
Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
Aziz Zaanan et al.
CLINICAL CANCER RESEARCH (2011)
Lymph Node Micrometastases and Isolated Tumor Cells Influence Survival in Stage I and II Colon Cancer
Arne E. Faerden et al.
DISEASES OF THE COLON & RECTUM (2011)
Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581
Donna Niedzwiecki et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Greg Yothers et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Gordon Hutchins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer-A Study of CALGB 9581 and 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Farina-Sarasqueta et al.
ANNALS OF ONCOLOGY (2010)
Prognostic Value of Perineural Invasion in Patients with Stage II Colorectal Cancer
Jung Wook Huh et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery
D-W Yan et al.
BRITISH JOURNAL OF CANCER (2010)
Carcinoma obstruction of the proximal colon cancer and long-term prognosis-obstruction is a predictor of worse outcome in TNM stage II tumor
Chih-Chien Chin et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2010)
Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer
Pei-Rong Ding et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2010)
Combination of Microsatellite Instability and Lymphocytic Infiltrate as a Prognostic Indicator for Adjuvant Therapy in Colon Cancer
Sandeep Kumar et al.
ARCHIVES OF SURGERY (2009)
Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy
Ralf Gertler et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prognostic value of PRL-3 overexpression in early stages of colonic cancer
Xiaofang Xing et al.
HISTOPATHOLOGY (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Daniel Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Lymph Node Ratio Is a Powerful Prognostic Factor of NodePositive Colon Cancers Undergoing Potentially Curative Surgery
Gennaro Galizia et al.
WORLD JOURNAL OF SURGERY (2009)
Clinical Significance of Lymph Node Micrometastasis in Stage I and II Colon Cancer
Sun Jin Park et al.
Cancer Research and Treatment (2009)
A study of lymph node ratio as a prognostic marker in colon cancer
K. Derwinger et al.
EJSO (2008)
Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression?
J. M. Fernandez-Cebrian et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2007)
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients:: Final results of GERCOR c96.1
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
J. Philip Kuebler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma
Ho-Young Lee et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic significance of thrombocytosis in node-negative colon cancer
EG Kandemir et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2005)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer:: Who benefits and by how much?
S Gill et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
